Tag: Carbonic Anhydrase Inhibitor
-
Apnimed Reports Positive Phase 2 Results for Sulthiame in Obstructive Sleep Apnea Published in The Lancet
Groundbreaking Phase 2 Results for Sulthiame in Obstructive Sleep Apnea Apnimed has announced that its Phase 2 FLOW study evaluating sulthiame, an oral carbonic anhydrase inhibitor, met the primary endpoint across all dosing regimens and demonstrated statistically significant improvements across multiple efficacy measures for obstructive sleep apnea (OSA). The positive findings were published in The…
-
Apnimed Publishes Positive Phase 2 Flow Study Results for Sulthiame in Obstructive Sleep Apnea in The Lancet
Overview: Promising Phase 2 Results in The Lancet Apnimed has announced that positive Phase 2 results from the FLOW study evaluating sulthiame, an oral carbonic anhydrase inhibitor, have been published in The Lancet. The publication highlights that sulthiame met the primary endpoint across all tested doses and significantly improved a range of efficacy measures in…
-
Apnimed Announces Lancet Publication: Positive Phase 2 Results for Sulthiame in Obstructive Sleep Apnea
New Lancet Publication Highlights Positive Phase 2 Outcomes Apnimed has revealed breakthrough findings from its Phase 2 FLOW study, showing that sulthiame, an oral carbonic anhydrase inhibitor, met the primary endpoint across all doses tested in obstructive sleep apnea (OSA). The Lancet publication details how sulthiame not only achieved statistical significance on primary measures but…